Amiodarone Zydus

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Amiodarone Zydus

What is Amiodarone Zydus?

Amiodarone Zydus is a prescription-only pharmaceutical preparation manufactured by Zydus, containing the active ingredient Amiodarone Hydrochloride. This medicine is categorized as a cardiovascular agent and an antiarrhythmic agent used to stabilize severe, life-threatening disruptions to the normal heart rhythm, particularly when other initial treatments have not been effective.

Classification as a Unique Broad-Spectrum Antiarrhythmic

The active ingredient, Amiodarone Hydrochloride, is classified as a Class III antiarrhythmic agent under the Vaughan Williams' system. This designation refers to its action of prolonging the electrical recovery period in the heart muscle. Amiodarone offers a robust antiarrhythmic effect and is utilized in complex cardiac scenarios to prevent dangerously fast or chaotic signals.

Unlike typical single-class antiarrhythmics, Amiodarone is distinguished by its broad-spectrum profile, which includes electrophysiological effects across all four Vaughan Williams' classes. This influence over multiple electrical pathways—potassium, sodium, and calcium channels—is a key factor in its clinical application for managing refractory arrhythmias.

Composition and Synthetic Chemical Origin

The oral tablet formulation of Amiodarone Zydus contains Amiodarone Hydrochloride as a single-active ingredient product. Amiodarone is a synthetic organic compound, structurally identified as a benzofuran derivative.

A significant feature of its composition is that the molecule is iodine-rich, containing approximately 37.3% iodine by weight. The substance is also characterized by high lipid solubility, which leads to an unusually long elimination half-life. This distinguishes its pharmacokinetics from most other heart rhythm medications and supports its use for long-term rhythm stabilization.

Regulatory References

  1. NIH StatPearls: Antiarrhythmic Medications
  2. FDA Full Prescribing Information
Advertisements

What side effects are possible with Amiodarone Zydus?

Amiodarone use is associated with substantial toxicity, including the risk of fatal pulmonary, hepatic, and cardiac adverse reactions, which are highlighted in regulatory warnings. Its use is generally reserved for treating life-threatening ventricular arrhythmias.

Serious and Clinically Significant Adverse Reactions

  • Pulmonary Toxicity: Occurs in up to 17% of patients in some series and can be fatal. This includes interstitial pneumonitis, hypersensitivity pneumonitis, or Adult Respiratory Distress Syndrome (ARDS) postoperatively. Symptoms may include cough, fever, and progressive shortness of breath.
  • Hepatotoxicity: Amiodarone can cause severe, sometimes fatal, liver injury. While asymptomatic elevations of liver enzymes are common, the risk includes a pathology resembling alcoholic hepatitis or cirrhosis. Monitoring of liver function is mandatory.
  • Worsened Arrhythmia: The drug can exacerbate existing arrhythmias (proarrhythmia) or induce new ones, such as Torsade de Pointes (TdP).
  • Thyroid Abnormalities: Both hypothyroidism (underactive) and hyperthyroidism (overactive) can occur and may be severe, requiring baseline and periodic monitoring of thyroid function.
  • Visual Impairment: Corneal microdeposits are very common and usually reversible, but rare cases of optic neuropathy/neuritis can lead to permanent blindness. Regular ophthalmic examination is recommended.

Other Common and Safety Notes

Common adverse reactions (occurring in ge 1% of patients) often include nausea, vomiting, constipation, headache, and peripheral neuropathy. Because of its long half-life (which can be several weeks or months), adverse reactions can persist following discontinuation. The drug also causes marked photosensitivity, and prolonged sun exposure may lead to a blue-gray discoloration of the skin. Amiodarone is contraindicated in patients with cardiogenic shock, certain types of heart block, or bradycardia without a functioning pacemaker, and during pregnancy or breastfeeding.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Emergency Medical Help

Amiodarone overdose is a serious medical event that can have a fatal outcome due to the potential for severe cardiac rhythm disturbances. Immediate medical attention is required if an overdose is suspected or occurs.

Overdose Manifestations

Symptoms and signs of an acute overdose primarily involve the cardiovascular and hepatic systems, and may include:

  • Cardiovascular: Extremely slow heartbeat (bradycardia), low blood pressure (hypotension), cardiac shock, and atrioventricular (AV) block.
  • Other Manifestations: Nausea, blurred vision, lightheadedness, and fainting.
  • Hepatic: Potential for liver toxicity.

Required Emergency Actions

If you take too much Amiodarone Zydus, you must call your healthcare provider or go to the nearest hospital emergency room right away. Management involves supportive treatment and close monitoring of cardiac rhythm and blood pressure.

Specific medical interventions may include the use of positive inotropic or vasopressor agents for low blood pressure, and a beta-adrenergic agonist or temporary pacemaker to manage severe bradycardia or heart block. It is important to know that amiodarone and its main metabolite are not removed by dialysis.

Due to the persistent presence of the drug in the body for an extended period, the effects of an overdose, including adverse reactions and drug interactions, may continue for several weeks after discontinuation.

Advertisements

Therapeutic Uses of Amiodarone Zydus

What Amiodarone Zydus Treats: Main Uses and Benefits

The therapeutic application of Amiodarone Zydus is commonly used to help with rhythm stabilization in conditions involving severe, life-threatening heart rhythm disturbances and highly symptomatic atrial conditions. The medication may be part of symptomatic management in situations where patients experience certain types of serious ventricular arrhythmias when other treatments have failed or could not be tolerated.


Stabilization and Rhythm Control

Amiodarone Zydus is predominantly used to help with managing and preventing the recurrence of severe, life-threatening arrhythmias like recurrent ventricular fibrillation (VF) and unstable ventricular tachycardia (VT). This medication is applied when appropriate in situations where conditions are refractory (have not responded) to other therapeutic options. It is also commonly used to help with managing supraventricular tachyarrhythmias, including atrial fibrillation (AF) and atrial flutter (AFl). This medication is considered relevant for patients with underlying structural heart disease or congestive heart failure.

The core benefit is rhythm stabilization, which may assist with maintaining functional stability during recurrent symptomatic episodes. This contributes to easing the overall symptom load by helping to relieve the distressing symptoms of palpitations and fatigue, and may assist with managing episodes that necessitate device intervention from an Implantable Cardioverter-Defibrillator (ICD).

“It is commonly used to help with rhythm control by supporting the attempt to achieve and maintain a normal sinus rhythm, assisting with maintaining functional stability.”


Quick Fact: Relief for Recurrent Palpitations

Regulatory References

  1. U.S. National Library of Medicine (NIH) MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Amiodarone Zydus is officially reserved for a highly specific and limited adult patient population with documented, life-threatening ventricular arrhythmias that have been refractory to, or intolerant of, other antiarrhythmic agents.

Populations Who Must Not Use (Contraindicated)

The medicine is strictly contraindicated in patients with the following conditions, unless a functioning pacemaker is present:

  • Cardiogenic Shock.
  • Sick Sinus Syndrome, Second-Degree, or Third-Degree Atrioventricular (AV) Block.
  • Bradycardia (slow heart rate) leading to syncope.
  • Known hypersensitivity to amiodarone, product components, or iodine.
  • Use is prohibited in combination with other medicinal products known to induce Torsades de Pointes.

Restricted and Special Population Eligibility

Age or Physiological Group Official Regulatory Status
Pediatric Population (Children) Safety and efficacy have not been established; use is generally not recommended.
Pregnancy Assigned FDA Pregnancy Category D (fetal risk documented); use is not recommended except in life-threatening situations.
Lactation (Breastfeeding) Not recommended; the mother should be advised to discontinue nursing as the drug passes into human milk.
Renal/Hepatic Impairment No official dosage adjustment is defined for renal or hepatic impairment; however, caution and close monitoring are advised.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define the interaction profile of Amiodarone Hydrochloride based on its dual effect as a potent inhibitor of drug metabolism and a compound that affects cardiac electrical stability.

Pharmacokinetic and Pharmacodynamic Interactions

Amiodarone is officially documented as inhibiting multiple key metabolic enzymes, including CYP1A2, CYP2C9, CYP2D6, CYP3A, and the P-glycoprotein ( P-gp) drug transporter. This pharmacokinetic inhibition reduces the clearance of co-administered medicines, such as Warfarin, Digoxin, and certain Statins (e.g., Simvastatin, Lovastatin), necessitating mandated dose limitations or reductions for these substances.

Pharmacodynamic interactions involve additive effects on the heart's electrical system. Co-administration with medicinal products that prolong the QT interval (e.g., Class Ia antiarrhythmics, specific antipsychotics) is contraindicated due to the high risk of Torsade de Pointes ( TdP). Similarly, combining the drug with HCV direct-acting antivirals (e.g., Sofosbuvir) is restricted due to the potential for severe bradycardia.

Administration and Timing Constraints

Due to the drug's unusually long elimination half-life, the risk of interactions officially persists for several weeks following the discontinuation of Amiodarone. A high-fat meal significantly increases the drug's oral absorption and exposure, requiring consistency in administration relative to food. Grapefruit Juice is explicitly advised against as it can increase the drug's plasma levels.

Advertisements

Mechanism of Action

Prolonging the Heart's Electrical Recovery Period

The primary mechanism involves the inhibition of potassium ( K^+) channels in the heart muscle cells, an action that significantly delays the repolarization phase of the cardiac action potential. This delay extends the Effective Refractory Period (ERP), making the heart tissue less electrically excitable and contributing to the suppression of re-entrant electrical pathways.


Modulating Conduction and Autonomic Signals

Amiodarone also blocks sodium ( Na^+) and L-type calcium ( Ca^2+) channels, which slows the speed of electrical signal transmission, particularly through the Atrioventricular (AV) node. Simultaneously, the drug acts as an antagonist at beta and alpha Adrenergic Receptors, which reduces the stimulatory effect of the sympathetic nervous system on the heart's automaticity and myocardial responsiveness.


Sustained Action via Active Metabolite and Accumulation

The prolonged electrophysiological change is maintained by the drug's high lipid solubility, which leads to slow accumulation in heart tissue, and the fact that its active metabolite, Desethylamiodarone ( DEA), also contributes to the multi-channel blockade. This dependence on accumulation explains why the comprehensive, stable antiarrhythmic mechanism takes an extended period to fully develop.

Advertisements

Dosage and Administration Information

The administration of amiodarone is structured into distinct phases and routes, reflecting its use for severe heart rhythm disturbances. The medicine is primarily administered via the oral route (tablet) for long-term stabilization and via intravenous (IV) infusion for acute, in-hospital initiation and rapid control.

Oral Dosing Schedule

Phase Daily Dose Range Frequency
Loading 800 mg to 1600 mg Typically divided doses for approx 1 to 3 weeks
Intermediate 600 mg to 800 mg Divided doses for approx 1 month
Maintenance 100 mg to 400 mg Once daily

Administration Context

Oral tablets must be administered consistently with regard to meals (e.g., always with food) to manage the variability in drug absorption. Initial treatment and dose adjustments are typically performed under hospital or specialist supervision.

For the intravenous route, the initial 1000 mg is delivered in three distinct, precisely controlled infusion phases over the first 24 hours. The IV solution must be diluted in 5% Dextrose in water (D5W) and administered using a volumetric infusion pump to ensure the controlled delivery rate (e.g., 0.5 mg/min maintenance).

Dosing in specific populations is guided by the principle of using the minimum effective dose; for instance, older adults are advised to begin treatment at the lower end of the adult dosing range. Furthermore, the safety and efficacy of amiodarone have not been established for pediatric use.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Amiodarone Zydus

The research base for Amiodarone Zydus (Amiodarone Hydrochloride) is structured around clinical trials and observational studies. These studies were primarily conducted to examine patterns related to heart rhythm and related outcomes, particularly in patients with severe heart conditions who had limited response to other approaches. These findings describe group patterns and observed changes in study populations.


Evidence for Use in Life-Threatening Ventricular Arrhythmias

Studies focused on severe, recurrent ventricular rhythm disturbances (like Ventricular Fibrillation and unstable Ventricular Tachycardia) have primarily used Randomized Controlled Trials (RCTs). These studies included adults with refractory arrhythmias that had not responded to other antiarrhythmic approaches. Research monitored endpoints such as the frequency of recurrent episodes and measurements related to the number of shocks delivered by an Implantable Cardioverter-Defibrillator (ICD).

Findings describe patterns observed in studies related to the frequency of severe rhythm disturbances in monitored populations. Data show patterns related to monitored heart rhythm status over follow-up periods. Despite the existence of controlled trials, certainty remains low regarding observations of all-cause total survival in certain high-risk groups, such as those with recent heart attacks.

Evidence for Managing Supraventricular Tachyarrhythmias

Research for conditions like Atrial Fibrillation (AF) and Atrial Flutter (AFl) includes clinical trials and observational cohorts. Studies explored use in adults with highly symptomatic or complex cases. Research examined endpoints related to the achievement and maintenance of a normal sinus rhythm and patient-reported outcomes describing discomfort.

Studies reported how symptoms evolved, indicating patterns of rhythm conversion and stability. Comparative evidence is lacking against some other antiarrhythmic drugs, and findings were mixed across various subtypes of supraventricular arrhythmias. Data for certain patient groups remain insufficient.

Research Focus on Patients with Structural Heart Disease and Heart Failure

Multiple multi-center trials and meta-analyses focused on patients with structural heart disease or Congestive Heart Failure (CHF). Studies monitored endpoints linked to total all-cause mortality, cardiovascular mortality, and changes in the heart's pumping fraction.

Studies reported observations related to mortality compared to control groups in certain chronic heart failure populations. However, findings were mixed across the individual trials, with some research describing patterns of no measured difference in total survival for the overall study group. Research highlights changes measured regarding the rate of sudden death in these cohorts.

What is Still Uncertain About Amiodarone Zydus Research

Research highlights what is known and outlines areas that are still uncertain. Long-term observations after five years are not fully established, particularly concerning non-cardiac outcomes. Findings were mixed in trials, and data are still emerging regarding the drug's influence on total all-cause survival in high-risk groups, indicating that certainty remains low in this area.

Key Studies & References

  1. Amiodarone: MedlinePlus Drug Information (U.S. National Library of Medicine)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Amiodarone Zydus (FAQ)

Q: How quickly should I feel a difference after starting Amiodarone Zydus?

A: The onset of the full antiarrhythmic effect of oral amiodarone is slow. Official product information indicates that therapeutic effects are usually not seen before 2 to 3 days and commonly take 1 to 3 weeks to develop, even when the initial higher 'loading' doses are used.

Q: Is Amiodarone Zydus safe for older people, like those over 75?

A: Regulatory documents advise that older patients should generally be started at the low end of the adult dosing range. This generally reflects the need for careful management and monitoring in this population, consistent with using the minimum effective dose.

Q: Can people with kidney problems safely take Amiodarone Zydus?

A: According to official prescribing information, amiodarone is eliminated primarily by the liver, and very little is excreted in the urine. Official information notes that kidney disease is generally not considered to have a marked effect on the disposition of the drug.

Q: Do children ever take Amiodarone Zydus for heart rhythm issues?

A: The official product labeling for amiodarone explicitly states that its safety and effectiveness have not been established in pediatric patients (children). Therefore, it is typically not authorized for use in this population.

Q: Is it true that Amiodarone Zydus can change the color of the skin?

A: Yes, official warnings list a skin reaction known as blue-gray discoloration as a possible side effect of amiodarone treatment. This is a noticeable, though rare, long-term effect.

Q: What is Amiodarone Zydus actually used for, besides just heart rhythm problems?

A: Amiodarone is officially indicated only for the treatment of specific, life-threatening, recurrent ventricular arrhythmias (severe irregular heart rhythms) that have not responded to other medications. The official label does not list indications for other, non-arrhythmia conditions.

Q: Is Amiodarone Zydus the same as regular Amiodarone?

A: Amiodarone Zydus contains the active ingredient Amiodarone hydrochloride. The U.S. FDA and other regulatory bodies have approved generic versions of oral amiodarone, meaning they contain the same active ingredient and are required to be bioequivalent to the original brand-name product.

Q: What are the most common side effects people complain about online with Amiodarone Zydus?

A: Common side effects reported in clinical trials include vision changes like corneal microdeposits, stomach upset (nausea, vomiting, constipation), fatigue, tremor, and lack of coordination. These are generally listed in the official Adverse Reactions sections.

Q: Does Amiodarone Zydus cause any long-term effects on the lungs or thyroid?

A: Yes, official warnings highlight that Amiodarone can cause serious, potentially fatal pulmonary toxicity (lung damage) and can also cause serious thyroid dysfunction, leading to either an overactive (hyperthyroidism) or underactive (hypothyroidism) gland.

Q: Are there any specific foods I need to avoid when taking this medication?

A: Yes, official product information includes a specific warning to avoid grapefruit juice and eating grapefruit. This is because grapefruit can increase the concentration of amiodarone in the body, potentially raising the risk of side effects.

Q: Does Amiodarone Zydus interact with common over-the-counter pain relievers?

A: Amiodarone is known to inhibit certain liver enzymes, meaning it can interact with many other drugs. This includes some ingredients found in common over-the-counter medications, and regulatory documents note that interactions may occur, which may require clinical attention.

Q: Can Amiodarone Zydus cause skin sensitivity to the sun?

A: Yes, photosensitivity (increased sensitivity to sunlight) is a reported side effect of amiodarone. Because photosensitivity is reported, sun protection measures are generally noted as important when using this medication.

Q: Is it normal to feel tired or weak when first starting Amiodarone Zydus?

A: Yes, regulatory documents list both fatigue and weakness among the common adverse reactions reported in patients taking amiodarone. You may experience these feelings when you first start treatment.

Q: Are there any known interactions between Amiodarone Zydus and blood thinners?

A: Yes, Amiodarone is known to significantly interact with certain anticoagulants (blood thinners) like warfarin. The interaction may increase the blood thinner’s effect, meaning careful monitoring is necessary during concurrent use.

Q: Can Amiodarone Zydus be taken with supplements like magnesium or potassium?

A: The official label includes a warning regarding the importance of correcting low magnesium or potassium levels before starting amiodarone. Because of this, clinical monitoring of these electrolyte levels is generally required during therapy.

Q: Does Amiodarone Zydus affect liver function?

A: Yes, Amiodarone can cause liver injury. While it is often mild and reversible, regulatory documents warn that severe, potentially fatal hepatotoxicity (liver damage) has been reported.

Q: Is there a generic version of Amiodarone Zydus that is cheaper?

A: Yes, the active ingredient, amiodarone, is available as generic tablets. Generic versions are FDA-approved and commercially available as alternatives to brand-specific products.

Q: Can this medication cause changes in vision or eye problems?

A: Yes, the official warnings mention that amiodarone can cause corneal deposits (small deposits on the front of the eye), blurred vision, and optic neuropathy, which is a condition that can potentially lead to permanent vision loss.

Q: Does taking Amiodarone Zydus affect driving ability?

A: Regulatory information indicates that side effects such as vision changes, dizziness, and a lack of motor coordination may occur. These effects could potentially impair a person's ability to drive or operate machinery safely.

Q: Are there any studies comparing Amiodarone Zydus to placebo for specific heart conditions?

A: Yes, regulatory documents and official reviews reference multiple clinical studies and meta-analyses. These studies confirm that amiodarone is effective compared to a placebo for certain outcomes related to controlling heart rhythms.

Q: Can Amiodarone Zydus cause changes in weight?

A: Changes in body weight are listed as symptoms associated with the thyroid problems (both hypo- and hyperthyroidism) that amiodarone is known to cause. This means both weight loss and weight gain can be indirect effects.

Q: Are there differences in how Amiodarone Zydus works in men versus women?

A: Official information regarding the drug's movement and processing in the body (pharmacokinetics) suggests that sex does not have a marked effect on how amiodarone or its active metabolite are processed.

Q: Does Amiodarone Zydus have any interaction with common cold or flu medications?

A: Due to amiodarone's ability to inhibit liver enzymes, it can interact with many medications. This includes some ingredients often found in cold and flu remedies, such as dextromethorphan. Caution is generally advised due to the potential for interaction.

Q: Is Amiodarone Zydus used for ventricular or atrial arrhythmias, or both?

A: In the United States, amiodarone is officially indicated only for the treatment of specific, life-threatening recurrent ventricular arrhythmias. Some international bodies may list uses for other arrhythmias like atrial fibrillation as well.

Q: What is the connection between Amiodarone Zydus and thyroid issues?

A: Amiodarone contains a large amount of iodine, and this component is responsible for its potential to cause severe thyroid dysfunction. It can lead to either an underactive thyroid (hypothyroidism) or an overactive thyroid (hyperthyroidism).

Q: Why do I have to avoid grapefruit juice when on Amiodarone Zydus?

A: Grapefruit juice avoidance is necessary because it inhibits the CYP3A4 enzyme in the body, which is responsible for breaking down amiodarone. Inhibiting this enzyme can significantly increase the drug's concentration in the bloodstream, increasing the risk of side effects.

Q: How much does diet impact the effectiveness of Amiodarone Zydus?

A: Diet impacts amiodarone absorption significantly. Official documents state that tablets must be administered consistently with regard to meals (e.g., always with food) due to the variability in how the drug is absorbed from the stomach. You must also avoid grapefruit.

Q: What kind of studies support the long-term effectiveness of Amiodarone Zydus?

A: The efficacy of amiodarone is supported by several regulatory-referenced randomized controlled trials and subsequent meta-analyses. These studies confirm the drug's ability to help achieve and maintain normal heart rhythm over time.

Q: Why do some people call Amiodarone Zydus a 'last resort' heart medication?

A: This perception stems from two official facts: the drug is indicated only for life-threatening arrhythmias refractory to other agents, and it carries a Boxed Warning about its substantial toxicity, particularly affecting the lungs, liver, and thyroid.

Q: How can I tell if Amiodarone Zydus is actually working for my condition?

A: The reliable way to assess effectiveness is through regular clinical monitoring. However, patients may be able to sense improvement if symptoms related to the irregular heart rhythm, such as dizziness, shortness of breath, or a rapid, pounding heart rate, begin to improve.

Advertisements

How should Amiodarone Zydus be stored and disposed of?

How to Store and Dispose of Amiodarone Zydus?

This medication must be stored according to official regulatory specifications to maintain its stability and quality.

Storage Requirement Official Guidance
Temperature Store at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F).
Protection Keep the tablets in a tightly closed, light-resistant container and protect from light.
Handling Keep out of the reach of children and store only in the original container.
Disposal Safely dispose of any out-of-date or unused tablets. Disposal should follow established guidelines for non-flush list medicines, typically involving drug take-back programs or mixing with an unappealing substance before discarding in household trash.

These instructions, mandated by official regulatory documents, define the critical conditions for temperature control, light exposure, and packaging to ensure the drug's integrity, and emphasize the necessary precautions for safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Amiodarone Zydus found in:

A-Z Index: